Glasdegib

Drug Profile

Glasdegib

Alternative Names: Oral Hedgehog Inhibitor - Pfizer; PF 04; PF-04449913; PF-4449913; Smo Inhibitor - Pfizer; Sonic Hedgehog pathway inhibitor (PF 4449913) - Pfizer

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Netherlands Cancer Institute; Pfizer
  • Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
  • Phase I/II Chronic myelomonocytic leukaemia
  • Phase I Haematological malignancies
  • No development reported Solid tumours

Most Recent Events

  • 28 Apr 2017 Pfizer plans a phase I trial in Healthy volunteers (NCT03130556)
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 03 Dec 2016 Efficacy and adverse events data from a phase II trial in Myelodysplastic syndrome and Chronic myeloid leukaemia (Monotherapy, Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top